Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies

References

• Churchman LS, Weissman JS. Nascent transcript sequencing visualizes transcription at nucleotide resolution. Nature 2011; 469:368-73; PMID:21248844; https://doi.org/10.1038/nature09652
   PubMed Web of Science ®Google Scholar
• Hodges C, Bintu L, Lubkowska L, Kashlev M, Bustamante C. Nucleosomal fluctuations govern the transcription dynamics of RNA polymerase II. Science 2009; 325:626-8; PMID:19644123; https://doi.org/10.1126/science.1172926
   PubMed Web of Science ®Google Scholar
• Rivera CM, Ren B. Mapping human epigenomes. Cell 2013; 155:39-55; PMID:24074860; https://doi.org/10.1016/j.cell.2013.09.011
   PubMed Web of Science ®Google Scholar
• Bird A. Perceptions of epigenetics. Nature 2007; 447:396-8; PMID:17522671; https://doi.org/10.1038/nature05913
   PubMed Web of Science ®Google Scholar
• Henikoff S. Nucleosome destabilization in the epigenetic regulation of gene expression. Nat Rev Genet 2008; 9:15-26; PMID:18059368; https://doi.org/10.1038/nrg2206
   PubMed Web of Science ®Google Scholar
• Kaelin WG, Jr., McKnight SL. Influence of metabolism on epigenetics and disease. Cell 2013; 153:56-69; PMID:23540690; https://doi.org/10.1016/j.cell.2013.03.004
   PubMed Web of Science ®Google Scholar
• Furey TS, Sethupathy P. Genetics. Genetics driving epigenetics. Science 2013; 342:705-6; PMID:24202168; https://doi.org/10.1126/science.1246755
   PubMed Web of Science ®Google Scholar
• Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000; 403:41-5; PMID:10638745; https://doi.org/10.1038/47412
   PubMed Web of Science ®Google Scholar
• Stasevich TJ, Hayashi-Takanaka Y, Sato Y, Maehara K, Ohkawa Y, Sakata-Sogawa K, Tokunaga M, Nagase T, Nozaki N, McNally JG, et al. Regulation of RNA polymerase II activation by histone acetylation in single living cells. Nature 2014; 516:272-5; PMID:25252976; https://doi.org/10.1038/nature13714
   PubMed Web of Science ®Google Scholar
• Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129:823-37; PMID:17512414; https://doi.org/10.1016/j.cell.2007.05.009
   PubMed Web of Science ®Google Scholar
• Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, Harp LF, Ye Z, Lee LK, Stuart RK, Ching CW, et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 2009; 459:108-12; PMID:19295514; https://doi.org/10.1038/nature07829
   PubMed Web of Science ®Google Scholar
• Muller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, Miller EL, O'Connor MB, Kingston RE, Simon JA. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 2002; 111:197-208; PMID:12408864; https://doi.org/10.1016/S0092-8674(02)00976-5
   PubMed Web of Science ®Google Scholar
• Czermin B, Melfi R, McCabe D, Seitz V, Imhof A, Pirrotta V. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 2002; 111:185-96; PMID:12408863; https://doi.org/10.1016/S0092-8674(02)00975-3
   PubMed Web of Science ®Google Scholar
• Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489:57-74; PMID:22955616; https://doi.org/10.1038/nature11247
   PubMed Web of Science ®Google Scholar
• Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, Epstein CB, Zhang X, Wang L, Issner R, Coyne M, et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 2011; 473:43-9; PMID:21441907; https://doi.org/10.1038/nature09906
   PubMed Web of Science ®Google Scholar
• Hosogane M, Funayama R, Shirota M, Nakayama K. Lack of transcription triggers H3K27me3 accumulation in the gene body. Cell Rep 2016; 16:696-706; PMID:27396330; https://doi.org/10.1016/j.celrep.2016.06.034
   PubMed Web of Science ®Google Scholar
• Hosogane M, Funayama R, Nishida Y, Nagashima T, Nakayama K. Ras-induced changes in H3K27me3 occur after those in transcriptional activity. PLoS Genet 2013; 9:e1003698; PMID:24009517; https://doi.org/10.1371/journal.pgen.1003698
   PubMed Web of Science ®Google Scholar
• Shen Y, Yue F, McCleary DF, Ye Z, Edsall L, Kuan S, Wagner U, Dixon J, Lee L, Lobanenkov VV, et al. A map of the cis-regulatory sequences in the mouse genome. Nature 2012; 488:116-20; PMID:22763441; https://doi.org/10.1038/nature11243
   PubMed Web of Science ®Google Scholar
• Benayoun BA, Pollina EA, Ucar D, Mahmoudi S, Karra K, Wong ED, Devarajan K, Daugherty AC, Kundaje AB, Mancini E, et al. H3K4me3 breadth is linked to cell identity and transcriptional consistency. Cell 2014; 158:673-88; PMID:25083876; https://doi.org/10.1016/j.cell.2014.06.027
   PubMed Web of Science ®Google Scholar
• Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell 2012; 48:491-507; PMID:23200123; https://doi.org/10.1016/j.molcel.2012.11.006
   PubMed Web of Science ®Google Scholar
• Zippo A, Serafini R, Rocchigiani M, Pennacchini S, Krepelova A, Oliviero S. Histone crosstalk between H3S10ph and H4K16ac generates a histone code that mediates transcription elongation. Cell 2009; 138:1122-36; PMID:19766566; https://doi.org/10.1016/j.cell.2009.07.031
   PubMed Web of Science ®Google Scholar
• Basnet H, Su XB, Tan Y, Meisenhelder J, Merkurjev D, Ohgi KA, Hunter T, Pillus L, Rosenfeld MG. Tyrosine phosphorylation of histone H2A by CK2 regulates transcriptional elongation. Nature 2014; 516:267-71; PMID:25252977; https://doi.org/10.1038/nature13736
   PubMed Web of Science ®Google Scholar
• Schubeler D. Function and information content of DNA methylation. Nature 2015; 517:321-6; PMID:25592537; https://doi.org/10.1038/nature14192
   PubMed Web of Science ®Google Scholar
• Schultz MD, He Y, Whitaker JW, Hariharan M, Mukamel EA, Leung D, Rajagopal N, Nery JR, Urich MA, Chen H, et al. Human body epigenome maps reveal noncanonical DNA methylation variation. Nature 2015; 523:212-6; PMID:26030523; https://doi.org/10.1038/nature14465
   PubMed Web of Science ®Google Scholar
• Roadmap Epigenomics C, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, Kheradpour P, Zhang Z, Wang J, et al. Integrative analysis of 111 reference human epigenomes. Nature 2015; 518:317-30; PMID:25693563; https://doi.org/10.1038/nature14248
   PubMed Web of Science ®Google Scholar
• Romanoski CE, Glass CK, Stunnenberg HG, Wilson L, Almouzni G. Epigenomics: Roadmap for regulation. Nature 2015; 518:314-6; PMID:25693562; https://doi.org/10.1038/518314a
   PubMed Web of Science ®Google Scholar
• Sturm D, Bender S, Jones DT, Lichter P, Grill J, Becher O, Hawkins C, Majewski J, Jones C, Costello JF, et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer 2014; 14:92-107; PMID:24457416; https://doi.org/10.1038/nrc3655
   PubMed Web of Science ®Google Scholar
• Donaldson SS, Laningham F, Fisher PG. Advances toward an understanding of brainstem gliomas. J Clin Oncol 2006; 24:1266-72; PMID:16525181; https://doi.org/10.1200/JCO.2005.04.6599
   PubMed Web of Science ®Google Scholar
• Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tonjes M, Sill M, Bender S, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012; 22:425-37; PMID:23079654; https://doi.org/10.1016/j.ccr.2012.08.024
   PubMed Web of Science ®Google Scholar
• Zadeh G, Aldape K. ACVR1 mutations and the genomic landscape of pediatric diffuse glioma. Nat Genet 2014; 46:421-2; PMID:24769718; https://doi.org/10.1038/ng.2970
   PubMed Web of Science ®Google Scholar
• Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M, Morrison A, Lewis P, Bouffet E, Bartels U, et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 2014; 46:451-6; PMID:24705254; https://doi.org/10.1038/ng.2936
   PubMed Web of Science ®Google Scholar
• Funato K, Major T, Lewis PW, Allis CD, Tabar V. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science 2014; 346:1529-33; PMID:25525250; https://doi.org/10.1126/science.1253799
   PubMed Web of Science ®Google Scholar
• Herz HM, Morgan M, Gao X, Jackson J, Rickels R, Swanson SK, Florens L, Washburn MP, Eissenberg JC, Shilatifard A. Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling. Science 2014; 345:1065-70; PMID:25170156; https://doi.org/10.1126/science.1255104
   PubMed Web of Science ®Google Scholar
• Waldmann T, Schneider R. Targeting histone modifications–epigenetics in cancer. Curr Opin Cell Biol 2013; 25:184-9; PMID:23347561; https://doi.org/10.1016/j.ceb.2013.01.001
   PubMed Web of Science ®Google Scholar
• Swartling FJ, Savov V, Persson AI, Chen J, Hackett CS, Northcott PA, Grimmer MR, Lau J, Chesler L, Perry A, et al. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell 2012; 21:601-13; PMID:22624711; https://doi.org/10.1016/j.ccr.2012.04.012
   PubMed Web of Science ®Google Scholar
• Fontebasso AM, Schwartzentruber J, Khuong-Quang DA, Liu XY, Sturm D, Korshunov A, Jones DT, Witt H, Kool M, Albrecht S, et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol 2013; 125:659-69; PMID:23417712; https://doi.org/10.1007/s00401-013-1095-8
   PubMed Web of Science ®Google Scholar
• Lewis PW, Muller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, Garcia BA, Muir TW, Becher OJ, Allis CD. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013; 340:857-61; PMID:23539183; https://doi.org/10.1126/science.1232245
   PubMed Web of Science ®Google Scholar
• Li F, Mao G, Tong D, Huang J, Gu L, Yang W, Li GM. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell 2013; 153:590-600; PMID:23622243; https://doi.org/10.1016/j.cell.2013.03.025
   PubMed Web of Science ®Google Scholar
• Lu C, Jain SU, Hoelper D, Bechet D, Molden RC, Ran L, Murphy D, Venneti S, Hameed M, Pawel BR, et al. Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape. Science 2016; 352:844-9; PMID:27174990; https://doi.org/10.1126/science.aac7272
   PubMed Web of Science ®Google Scholar
• Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 2013; 45:1479-82; PMID:24162739; https://doi.org/10.1038/ng.2814
   PubMed Web of Science ®Google Scholar
• Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, Qu C, Ding L, Huether R, Parker M, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 2012; 44:251-3; PMID:22286216; https://doi.org/10.1038/ng.1102
   PubMed Web of Science ®Google Scholar
• Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tonjes M, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012; 482:226-31; PMID:22286061; https://doi.org/10.1038/nature10833
   PubMed Web of Science ®Google Scholar
• Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012; 13:916-26; PMID:22877848; https://doi.org/10.1016/S1470-2045(12)70265-6
   PubMed Web of Science ®Google Scholar
• Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012; 13:707-15; PMID:22578793; https://doi.org/10.1016/S1470-2045(12)70164-X
   PubMed Web of Science ®Google Scholar
• Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999; 59:793-7; PMID:10029064
   PubMed Web of Science ®Google Scholar
• Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al. The somatic genomic landscape of glioblastoma. Cell 2013; 155:462-77; PMID:24120142; https://doi.org/10.1016/j.cell.2013.09.034
   PubMed Web of Science ®Google Scholar
• Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse Glioma. Cell 2016; 164:550-63; PMID:26824661; https://doi.org/10.1016/j.cell.2015.12.028
   PubMed Web of Science ®Google Scholar
• Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17:510-22; PMID:20399149; https://doi.org/10.1016/j.ccr.2010.03.017
   PubMed Web of Science ®Google Scholar
• Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset PO, Bechet D, Faury D, De Jay N, Ramkissoon LA, et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet 2014; 46:462-6; PMID:24705250; https://doi.org/10.1038/ng.2950
   PubMed Web of Science ®Google Scholar
• Jones DT, Jager N, Kool M, Zichner T, Hutter B, Sultan M, Cho YJ, Pugh TJ, Hovestadt V, Stutz AM, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012; 488:100-5; PMID:22832583; https://doi.org/10.1038/nature11284
   PubMed Web of Science ®Google Scholar
• Lin CY, Erkek S, Tong Y, Yin L, Federation AJ, Zapatka M, Haldipur P, Kawauchi D, Risch T, Warnatz HJ, et al. Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature 2016; 530:57-62; PMID:26814967; https://doi.org/10.1038/nature16546
   PubMed Web of Science ®Google Scholar
• Tang Y, Gholamin S, Schubert S, Willardson MI, Lee A, Bandopadhayay P, Bergthold G, Masoud S, Nguyen B, Vue N, et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med 2014; 20:732-40; PMID:24973920; https://doi.org/10.1038/nm.3613
   PubMed Web of Science ®Google Scholar
• Bandopadhayay P, Bergthold G, Nguyen B, Schubert S, Gholamin S, Tang Y, Bolin S, Schumacher SE, Zeid R, Masoud S, et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res 2014; 20:912-25; PMID:24297863; https://doi.org/10.1158/1078-0432.CCR-13-2281
   PubMed Web of Science ®Google Scholar
• Hovestadt V, Jones DT, Picelli S, Wang W, Kool M, Northcott PA, Sultan M, Stachurski K, Ryzhova M, Warnatz HJ, et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature 2014; 510:537-41; PMID:24847876; https://doi.org/10.1038/nature13268
   PubMed Web of Science ®Google Scholar
• Morrissy AS, Garzia L, Shih DJ, Zuyderduyn S, Huang X, Skowron P, Remke M, Cavalli FM, Ramaswamy V, Lindsay PE, et al. Divergent clonal selection dominates medulloblastoma at recurrence. Nature 2016; 529:351-7; PMID:26760213; https://doi.org/10.1038/nature16478
   PubMed Web of Science ®Google Scholar
• Yao Y, Mack SC, Taylor MD. Molecular genetics of ependymoma. Chin J Cancer 2011; 30:669-81; PMID:21959044; https://doi.org/10.5732/cjc.011.10129
   PubMedGoogle Scholar
• Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, Benner A, Hielscher T, Milde T, Remke M, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 2011; 20:143-57; PMID:21840481; https://doi.org/10.1016/j.ccr.2011.07.007
   PubMed Web of Science ®Google Scholar
• Johnson RA, Wright KD, Poppleton H, Mohankumar KM, Finkelstein D, Pounds SB, Rand V, Leary SE, White E, Eden C, et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 2010; 466:632-6; PMID:20639864; https://doi.org/10.1038/nature09173
   PubMed Web of Science ®Google Scholar
• Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stutz AM, Wang X, Gallo M, Garzia L, Zayne K, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 2014; 506:445-50; PMID:24553142; https://doi.org/10.1038/nature13108
   PubMed Web of Science ®Google Scholar
• Hilden JM, Meerbaum S, Burger P, Finlay J, Janss A, Scheithauer BW, Walter AW, Rorke LB, Biegel JA. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol 2004; 22:2877-84; PMID:15254056; https://doi.org/10.1200/JCO.2004.07.073
   PubMed Web of Science ®Google Scholar
• Jagani Z, Mora-Blanco EL, Sansam CG, McKenna ES, Wilson B, Chen D, Klekota J, Tamayo P, Nguyen PT, Tolstorukov M, et al. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med 2010; 16:1429-33; PMID:21076395; https://doi.org/10.1038/nm.2251
   PubMed Web of Science ®Google Scholar
• Versteege I, Medjkane S, Rouillard D, Delattre O. A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle. Oncogene 2002; 21:6403-12; PMID:12226744; https://doi.org/10.1038/sj.onc.1205841
   PubMed Web of Science ®Google Scholar
• Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, Cho YJ, Koellhoffer EC, Pomeroy SL, Orkin SH, Roberts CW. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 2010; 18:316-28; PMID:20951942; https://doi.org/10.1016/j.ccr.2010.09.006
   PubMed Web of Science ®Google Scholar
• Alimova I, Birks DK, Harris PS, Knipstein JA, Venkataraman S, Marquez VE, Foreman NK, Vibhakar R. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. Neuro Oncol 2013; 15:149-60; PMID:23190500; https://doi.org/10.1093/neuonc/nos285
   PubMed Web of Science ®Google Scholar
• Algar EM, Muscat A, Dagar V, Rickert C, Chow CW, Biegel JA, Ekert PG, Saffery R, Craig J, Johnstone RW, et al. Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors. PLoS One 2009; 4:e4482; PMID:19221586; https://doi.org/10.1371/journal.pone.0004482
   PubMed Web of Science ®Google Scholar
• Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362:2202-11; PMID:20558371; https://doi.org/10.1056/NEJMra0804577
   PubMed Web of Science ®Google Scholar
• Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov 2013; 3:308-23; PMID:23430699; https://doi.org/10.1158/2159-8290.CD-12-0418
   PubMed Web of Science ®Google Scholar
• Zahnow CA, Topper M, Stone M, Murray-Stewart T, Li H, Baylin SB, Casero RA, Jr. Inhibitors of DNA methylation, histone deacetylation, and histone demethylation: A perfect combination for cancer therapy. Adv Cancer Res 2016; 130:55-111; PMID:27037751; https://doi.org/10.1016/bs.acr.2016.01.007
   PubMed Web of Science ®Google Scholar
• Song Y, Wu F, Wu J. Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives. J Hematol Oncol 2016; 9:49; PMID:27316347; https://doi.org/10.1186/s13045-016-0279-9
   PubMed Web of Science ®Google Scholar
• Popovic R, Licht JD. Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov 2012; 2:405-13; PMID:22588878; https://doi.org/10.1158/2159-8290.CD-12-0076
   PubMed Web of Science ®Google Scholar
• McGrath J, Trojer P. Targeting histone lysine methylation in cancer. Pharmacol Ther 2015; 150:1-22; PMID:25578037; https://doi.org/10.1016/j.pharmthera.2015.01.002
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu K, Qin S, Xu C, Min J. Epigenetic targets and drug discovery: part 1: histone methylation. Pharmacol Ther 2014; 143:275-94; PMID:24704322; https://doi.org/10.1016/j.pharmthera.2014.03.007
   PubMed Web of Science ®Google Scholar
• Liu K, Liu Y, Lau JL, Min J. Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA methylation. Pharmacol Ther 2015; 151:121-40; PMID:25857453; https://doi.org/10.1016/j.pharmthera.2015.04.001
   PubMed Web of Science ®Google Scholar
• Arcipowski KM, Martinez CA, Ntziachristos P. Histone demethylases in physiology and cancer: a tale of two enzymes, JMJD3 and UTX. Curr Opin Genet Dev 2016; 36:59-67; PMID:27151432; https://doi.org/10.1016/j.gde.2016.03.010
   PubMed Web of Science ®Google Scholar
• Yang Y, Bedford MT. Protein arginine methyltransferases and cancer. Nat Rev Cancer 2013; 13:37-50; PMID:23235912; https://doi.org/10.1038/nrc3409
   PubMed Web of Science ®Google Scholar
• Ezponda T, Licht JD. Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination. Clin Cancer Res 2014; 20:5001-8; PMID:24987060; https://doi.org/10.1158/1078-0432.CCR-13-2499
   PubMed Web of Science ®Google Scholar
• De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, Helin K, Hornick JL, Mautner V, Kehrer-Sawatzki H, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 2014; 514:247-51; PMID:25119042; https://doi.org/10.1038/nature13561
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455:1061-8; PMID:18772890; https://doi.org/10.1038/nature07385
   PubMed Web of Science ®Google Scholar
• Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, Waghorn K, Zoi K, Ross FM, Reiter A, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42:722-6; PMID:20601953; https://doi.org/10.1038/ng.621
   PubMed Web of Science ®Google Scholar
• Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER, van der Heijden A, Scheele TN, Vandenberghe P, de Witte T, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42:665-7; PMID:20601954; https://doi.org/10.1038/ng.620
   PubMed Web of Science ®Google Scholar
• Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Flaherty MS, Ferres-Marco D, da Ros V, Tang Z, Siegle J, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012; 18:298-301; PMID:22237151; https://doi.org/10.1038/nm.2651
   PubMed Web of Science ®Google Scholar
• Ntziachristos P, Tsirigos A, Welstead GG, Trimarchi T, Bakogianni S, Xu L, Loizou E, Holmfeldt L, Strikoudis A, King B, et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature 2014; 514:513-7; PMID:25132549; https://doi.org/10.1038/nature13605
   PubMed Web of Science ®Google Scholar
• Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42:181-5; PMID:20081860; https://doi.org/10.1038/ng.518
   PubMed Web of Science ®Google Scholar
• Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Ezponda T, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013; 23:677-92; PMID:23680150; https://doi.org/10.1016/j.ccr.2013.04.011
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia E, Licht JD. Deregulation of H3K27 methylation in cancer. Nat Genet 2010; 42:100-1; PMID:20104248; https://doi.org/10.1038/ng0210-100
   PubMed Web of Science ®Google Scholar
• Bender S, Tang Y, Lindroth AM, Hovestadt V, Jones DT, Kool M, Zapatka M, Northcott PA, Sturm D, Wang W, et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 2013; 24:660-72; PMID:24183680; https://doi.org/10.1016/j.ccr.2013.10.006
   PubMed Web of Science ®Google Scholar
• Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, Gupta N, Mueller S, James CD, Jenkins R, et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev 2013; 27:985-90; PMID:23603901; https://doi.org/10.1101/gad.217778.113
   PubMed Web of Science ®Google Scholar
• Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, Porter Scott M, Chesworth R, Moyer MP, Copeland RA, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A 2013; 110:7922-7; PMID:23620515; https://doi.org/10.1073/pnas.1303800110
   PubMed Web of Science ®Google Scholar
• Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, Sacks JD, Raimondi A, Majer CR, Song J, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012; 8:890-6; PMID:23023262; https://doi.org/10.1038/nchembio.1084
   PubMed Web of Science ®Google Scholar
• Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, Oh YT, Kim H, Rheey J, Nakano I, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 2013; 23:839-52; PMID:23684459; https://doi.org/10.1016/j.ccr.2013.04.008
   PubMed Web of Science ®Google Scholar
• Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007; 21:1050-63; PMID:17437993; https://doi.org/10.1101/gad.1524107
   PubMed Web of Science ®Google Scholar
• Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, Marquez VE, Jones PA. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 2009; 8:1579-88; PMID:19509260; https://doi.org/10.1158/1535-7163.MCT-09-0013
   PubMed Web of Science ®Google Scholar
• McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A, 3rd, Diaz E, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492:108-12; PMID:23051747; https://doi.org/10.1038/nature11606
   PubMed Web of Science ®Google Scholar
• Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet 2013; 14:765-80; PMID:24105274; https://doi.org/10.1038/nrg3554
   PubMed Web of Science ®Google Scholar
• Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, Boca SM, Carter H, Samayoa J, Bettegowda C, et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011; 331:435-9; PMID:21163964; https://doi.org/10.1126/science.1198056
   PubMed Web of Science ®Google Scholar
• Dahlin AM, Hollegaard MV, Wibom C, Andersson U, Hougaard DM, Deltour I, Hjalmars U, Melin B. CCND2, CTNNB1, DDX3X, GLI2, SMARCA4, MYC, MYCN, PTCH1, TP53, and MLL2 gene variants and risk of childhood medulloblastoma. J Neurooncol 2015; 125:75-8; PMID:26290144; https://doi.org/10.1007/s11060-015-1891-1
   PubMed Web of Science ®Google Scholar
• Lopez GY, Grant GA, Fuchs HE, Leithe LG, Gururangan S, Bigner DD, Yan H, McLendon RE, He Y. Clinico-pathological description of three paediatric medulloblastoma cases with MLL2/3 gene mutations. Neuropathol Appl Neurobiol 2014; 40:217-20; PMID:23659599; https://doi.org/10.1111/nan.12060
   PubMed Web of Science ®Google Scholar
• Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, Carneiro MO, Carter SL, Cibulskis K, Erlich RL, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012; 488:106-10; PMID:22820256; https://doi.org/10.1038/nature11329
   PubMed Web of Science ®Google Scholar
• Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, Phoenix TN, Hedlund E, Wei L, Zhu X, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012; 488:43-8; PMID:22722829; https://doi.org/10.1038/nature11213
   PubMed Web of Science ®Google Scholar
• Gallo M, Ho J, Coutinho FJ, Vanner R, Lee L, Head R, Ling EK, Clarke ID, Dirks PB. A tumorigenic MLL-homeobox network in human glioblastoma stem cells. Cancer Res 2013; 73:417-27; PMID:23108137; https://doi.org/10.1158/0008-5472.CAN-12-1881
   PubMed Web of Science ®Google Scholar
• Gallo M, Coutinho FJ, Vanner RJ, Gayden T, Mack SC, Murison A, Remke M, Li R, Takayama N, Desai K, et al. MLL5 orchestrates a cancer self-renewal state by repressing the histone variant H3.3 and globally reorganizing chromatin. Cancer Cell 2015; 28:715-29; PMID:26626085; https://doi.org/10.1016/j.ccell.2015.10.005
   PubMed Web of Science ®Google Scholar
• Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, Doench JG, Xu H, Chu SH, Qi J, et al. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat Med 2015; 21:335-43; PMID:25822366; https://doi.org/10.1038/nm.3832
   PubMed Web of Science ®Google Scholar
• Li J, Yin C, Okamoto H, Mushlin H, Balgley BM, Lee CS, Yuan K, Ikejiri B, Glasker S, Vortmeyer AO, et al. Identification of a novel proliferation-related protein, WHSC1 4a, in human gliomas. Neuro Oncol 2008; 10:45-51; PMID:18182627; https://doi.org/10.1215/15228517-2007-036
   PubMed Web of Science ®Google Scholar
• Cheung N, Fung TK, Zeisig BB, Holmes K, Rane JK, Mowen KA, Finn MG, Lenhard B, Chan LC, So CW. Targeting aberrant epigenetic networks mediated by PRMT1 and KDM4C in acute myeloid leukemia. Cancer Cell 2016; 29:32-48; PMID:26766589; https://doi.org/10.1016/j.ccell.2015.12.007
   PubMed Web of Science ®Google Scholar
• Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, Pomeroy SL, Korshunov A, Lichter P, Taylor MD, et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer 2012; 12:818-34; PMID:23175120; https://doi.org/10.1038/nrc3410
   PubMed Web of Science ®Google Scholar
• Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150:1107-20; PMID:22980975; https://doi.org/10.1016/j.cell.2012.08.029
   PubMed Web of Science ®Google Scholar
• Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H, et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 2012; 488:404-8; PMID:22842901; https://doi.org/10.1038/nature11262
   PubMed Web of Science ®Google Scholar
• Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, Fang D, Huang X, Tom MW, Ngo V, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med 2014; 20:1394-6; PMID:25401693; https://doi.org/10.1038/nm.3716
   PubMed Web of Science ®Google Scholar
• Ramaswamy V, Remke M, Taylor MD. An epigenetic therapy for diffuse intrinsic pontine gliomas. Nat Med 2014; 20:1378-9; PMID:25473916; https://doi.org/10.1038/nm.3769
   PubMed Web of Science ®Google Scholar
• Morales La Madrid A, Hashizume R, Kieran MW. Future clinical trials in DIPG: Bringing epigenetics to the clinic. Front Oncol 2015; 5:148; PMID:26191506; https://doi.org/10.3389/fonc.2015.00148
   PubMed Web of Science ®Google Scholar
• Lulla RR, Saratsis AM, Hashizume R. Mutations in chromatin machinery and pediatric high-grade glioma. Sci Adv 2016; 2:e1501354; PMID:27034984; https://doi.org/10.1126/sciadv.1501354
   PubMed Web of Science ®Google Scholar
• Becher OJ, Wechsler-Reya RJ. Cancer. For pediatric glioma, leave no histone unturned. Science 2014; 346:1458-9; PMID:25525232; https://doi.org/10.1126/science.aaa3814
   PubMed Web of Science ®Google Scholar
• Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, Haydu JE, Rigo I, Hadler M, Tosello V, Della Gatta G, Paietta E, Racevskis J, et al. ETV6 mutations in early immature human T cell leukemias. J Exp Med 2011; 208:2571-9; PMID:22162831; https://doi.org/10.1084/jem.20112239
   PubMed Web of Science ®Google Scholar
• Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Lowenberg B, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350:1617-28; PMID:15084694; https://doi.org/10.1056/NEJMoa040465
   PubMed Web of Science ®Google Scholar
• Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, Zhao K. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009; 138:1019-31; PMID:19698979; https://doi.org/10.1016/j.cell.2009.06.049
   PubMed Web of Science ®Google Scholar
• Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, Mita M, Beck J, Burris H, Ryan G, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008; 14:4500-10; PMID:18628465; https://doi.org/10.1158/1078-0432.CCR-07-4262
   PubMed Web of Science ®Google Scholar
• Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, Quist MJ, Davis LE, Huang EC, Woo PJ, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med 2015; 21:555-9; PMID:25939062; https://doi.org/10.1038/nm.3855
   PubMed Web of Science ®Google Scholar
• Muscat A, Popovski D, Jayasekara WS, Rossello FJ, Ferguson M, Marini KD, Alamgeer M, Algar EM, Downie P, Watkins DN, et al. Low-dose histone deacetylase inhibitor treatment leads to tumor growth arrest and multi-lineage differentiation of malignant rhabdoid tumors. Clin Cancer Res 2016; 22:3560-70; PMID:26920892; https://doi.org/10.1158/1078-0432.CCR-15-2260
   PubMed Web of Science ®Google Scholar
• Bagcchi S. Panobinostat active against diffuse intrinsic pontine glioma. Lancet Oncol 2015; 16:e267; PMID:25971867; https://doi.org/10.1016/S1470-2045(15)70230-5
   PubMed Web of Science ®Google Scholar
• Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R, Gerard M, Schiff D, Chi AS, Batchelor TT, et al. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol 2012; 107:133-8; PMID:21984064; https://doi.org/10.1007/s11060-011-0717-z
   PubMed Web of Science ®Google Scholar
• Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F, Schwerkoske J, Mazurczak M, Gross H, Pajon E, et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol 2012; 14:215-21; PMID:22090453; https://doi.org/10.1093/neuonc/nor198
   PubMed Web of Science ®Google Scholar
• Sawa H, Murakami H, Kumagai M, Nakasato M, Yamauchi S, Matsuyama N, Tamura Y, Satone A, Ide W, Hashimoto I, et al. Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol 2004; 107:523-31; PMID:15024582; https://doi.org/10.1007/s00401-004-0841-3
   PubMed Web of Science ®Google Scholar
• Barker CA, Bishop AJ, Chang M, Beal K, Chan TA. Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys 2013; 86:504-9; PMID:23523186; https://doi.org/10.1016/j.ijrobp.2013.02.012
   PubMed Web of Science ®Google Scholar
• Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011; 77:1156-64; PMID:21880994; https://doi.org/10.1212/WNL.0b013e31822f02e1
   PubMed Web of Science ®Google Scholar
• Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17:330-9; PMID:21386836; https://doi.org/10.1038/nm.2305
   PubMed Web of Science ®Google Scholar
• Wadhwa E, Nicolaides T. Bromodomain inhibitor review: bromodomain and extra-terminal family protein inhibitors as a potential new therapy in central nervous system tumors. Cureus 2016; 8:e620; PMID:27382528; https://doi.org/10.7759/cureus.620
   PubMedGoogle Scholar
• Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. Selective inhibition of BET bromodomains. Nature 2010; 468:1067-73; PMID:20871596; https://doi.org/10.1038/nature09504
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 2014; 13:337-56; PMID:24751816; https://doi.org/10.1038/nrd4286
   PubMed Web of Science ®Google Scholar
• Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146:904-17; PMID:21889194; https://doi.org/10.1016/j.cell.2011.08.017
   PubMed Web of Science ®Google Scholar
• Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, Chandwani R, Marazzi I, Wilson P, Coste H, et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010; 468:1119-23; PMID:21068722; https://doi.org/10.1038/nature09589
   PubMed Web of Science ®Google Scholar
• Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011; 478:529-33; PMID:21964340; https://doi.org/10.1038/nature10509
   PubMed Web of Science ®Google Scholar
• Mirguet O, Gosmini R, Toum J, Clement CA, Barnathan M, Brusq JM, Mordaunt JE, Grimes RM, Crowe M, Pineau O, et al. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. J Med Chem 2013; 56:7501-15; PMID:24015967; https://doi.org/10.1021/jm401088k
   PubMed Web of Science ®Google Scholar
• Berenguer-Daize C, Astorgues-Xerri L, Odore E, Cayol M, Cvitkovic E, Noel K, Bekradda M, MacKenzie S, Rezai K, Lokiec F, et al. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. Int J Cancer 2016; 139:2047-55; PMID:27388964; https://doi.org/10.1002/ijc.30256
   PubMed Web of Science ®Google Scholar
• Henssen A, Thor T, Odersky A, Heukamp L, El-Hindy N, Beckers A, Speleman F, Althoff K, Schafers S, Schramm A, et al. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget 2013; 4:2080-95; PMID:24231268; https://doi.org/10.18632/oncotarget.1534
   PubMed Web of Science ®Google Scholar
• Pastori C, Daniel M, Penas C, Volmar CH, Johnstone AL, Brothers SP, Graham RM, Allen B, Sarkaria JN, Komotar RJ, et al. BET bromodomain proteins are required for glioblastoma cell proliferation. Epigenetics 2014; 9:611-20; PMID:24496381; https://doi.org/10.4161/epi.27906
   PubMed Web of Science ®Google Scholar
• Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce LA, Thompson RC, Muller S, Knapp S, Wang J. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res 2013; 19:1748-59; PMID:23403638; https://doi.org/10.1158/1078-0432.CCR-12-3066
   PubMed Web of Science ®Google Scholar
• Pastori C, Kapranov P, Penas C, Peschansky V, Volmar CH, Sarkaria JN, Bregy A, Komotar R, St Laurent G, Ayad NG, et al. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation. Proc Natl Acad Sci U S A 2015; 112:8326-31; PMID:26111795; https://doi.org/10.1073/pnas.1424220112
   PubMed Web of Science ®Google Scholar
• Nervi C, De Marinis E, Codacci-Pisanelli G. Epigenetic treatment of solid tumours: a review of clinical trials. Clin Epigenetics 2015; 7:127; PMID:26692909; https://doi.org/10.1186/s13148-015-0157-2
   PubMed Web of Science ®Google Scholar
• Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009; 27:2052-8; PMID:19307505; https://doi.org/10.1200/JCO.2008.19.0694
   PubMed Web of Science ®Google Scholar
• Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H, et al. Kruidenier et al. reply. Nature 2014; 514:E2; PMID:25279927; https://doi.org/10.1038/nature13689
   PubMed Web of Science ®Google Scholar
• Heinemann B, Nielsen JM, Hudlebusch HR, Lees MJ, Larsen DV, Boesen T, Labelle M, Gerlach LO, Birk P, Helin K. Inhibition of demethylases by GSK-J1/J4. Nature 2014; 514:E1-2; PMID:25279926; https://doi.org/10.1038/nature13688
   PubMed Web of Science ®Google Scholar
• Albert M, Schmitz SU, Kooistra SM, Malatesta M, Morales Torres C, Rekling JC, Johansen JV, Abarrategui I, Helin K. The histone demethylase Jarid1b ensures faithful mouse development by protecting developmental genes from aberrant H3K4me3. PLoS Genet 2013; 9:e1003461; PMID:23637629; https://doi.org/10.1371/journal.pgen.1003461
   PubMed Web of Science ®Google Scholar
• Gut P, Verdin E. The nexus of chromatin regulation and intermediary metabolism. Nature 2013; 502:489-98; PMID:24153302; https://doi.org/10.1038/nature12752
   PubMed Web of Science ®Google Scholar
• Koike N, Yoo SH, Huang HC, Kumar V, Lee C, Kim TK, Takahashi JS. Transcriptional architecture and chromatin landscape of the core circadian clock in mammals. Science 2012; 338:349-54; PMID:22936566; https://doi.org/10.1126/science.1226339
   PubMed Web of Science ®Google Scholar
• Etchegaray JP, Lee C, Wade PA, Reppert SM. Rhythmic histone acetylation underlies transcription in the mammalian circadian clock. Nature 2003; 421:177-82; PMID:12483227; https://doi.org/10.1038/nature01314
   PubMed Web of Science ®Google Scholar